|Articles|June 10, 2004

Three states pass tort reform legislation, two defeat it

New Jersey, Ohio, and Oklahoma have recently passed medical liability legislative reforms.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

Money Matters: How can you plan for your retirement income needs?

ByRonald J. Paprocki, JD, CFP, CHBC

May 29th 2026

Why RAG-based AI models may be more sufficient for patient education

ByArchan Khandekar, MD

May 26th 2026

From Washington to Rhode Island: Understanding new requirements for medical group governance

ByAmerican Association of Clinical Urology

May 25th 2026

Urology workforce stable but facing access and pipeline challenges, AUA Census finds

ByHung-Jui (Ray) Tan, MD, MSHPM

May 17th 2026

The UroOnc Minute: Emergency Hematuria Management, with Nikita R. Bhatt, MBBS, MCh, MMed, FRCS

ByAdam B. Weiner, MD,Nikita R. Bhatt, MBBS, MCh, MMed, FRCS

May 8th 2026

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Three states pass tort reform legislation, two defeat it

Related Content

Money Matters: How can you plan for your retirement income needs?

Why RAG-based AI models may be more sufficient for patient education

From Washington to Rhode Island: Understanding new requirements for medical group governance

Urology workforce stable but facing access and pipeline challenges, AUA Census finds

The UroOnc Minute: Emergency Hematuria Management, with Nikita R. Bhatt, MBBS, MCh, MMed, FRCS

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on Urology Times

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC

ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer